ScreenerHero

EBSEmergent BioSolutions Inc.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · emergentbiosolutions.com
5.080USD+3.89%Mkt Cap: 260.47M $P/E: —

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationall…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap260.47M $
Enterprise Value695.64M $
Revenue (TTM)770.20M $
Gross Profit379.00M $
Net Income (TTM)52.60M $
Revenue/Share14.76 USD
Last Price5.080 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees900
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS29089Q1058
Valuation
P/E (Trailing)—
P/E (Forward)1.61
PEG0.38
EV/EBITDA2.99
EV/Revenue0.90
P/S0.32
P/B0.72
EPS (TTM)-3.36
EPS (Forward)—
52W Range
4.3657% of range14.06
52W High14.06 USD
52W Low4.365 USD
Profitability
Gross Margin53.74%
Oper. Margin28.34%
EBITDA Margin30.17%
Profit Margin7.46%
ROE10.07%
ROA3.99%
Growth
Revenue Growth66.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF170.60M $
CapEx (TTM)13.80M $
FCF Margin4.87%
FCF Yield14.40%
Net Debt448.50M $
Net Debt/EBITDA1.93
Balance Sheet
Debt/Equity1.09
Current Ratio5.42
Quick Ratio2.69
Book Value/Sh6.655 USD
Cash/Share2.725 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.00 USD
Upside (mean)+116.5%
Target Range10.00 USD – 12.00 USD
$10.00+116.5% to mean$12.00
# Analysts2
Ownership
Shares Out.51.27M
Float49.06M
Insiders4.26%
Institutions90.67%
Short Interest
Short Ratio15.0d
Short % Float19.87%
Short % Out.19.56%
Shares Short10.03M
Short (prev mo.)10.27M
Technical
SMA 507.183 (-29.3%)
SMA 2009.283 (-45.3%)
Beta2.36
S&P 52W Chg18.16%
Avg Vol (30d)1.02M
Avg Vol (10d)1.80M
Technical Indicators
RSI (14)33.1
MACD-0.8348
MACD Signal-0.7605
MACD Hist.-0.0743
BB Upper8.809 USD
BB Middle6.046 USD
BB Lower3.283 USD
BB Width91.41%
ATR (14)0.3876 USD
Vol Ratio (20d)1.10x